Procarbazine
 |
|
 |
|
| Clinical data | |
|---|---|
| Trade names | Matulane, Natulan, Indicarb, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682094 |
| Pregnancy category |
|
| Routes of administration |
By mouth (gel capsule), intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | liver, kidney |
| Biological half-life | 10 minutes |
| Excretion | kidney |
| Identifiers | |
|
|
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| ECHA InfoCard | 100.010.531 |
| Chemical and physical data | |
| Formula | C12H19N3O |
| Molar mass | 221.299 g/mol |
| 3D model (Jmol) | |
|
|
|
|
  (what is this?)
|
|
Procarbazine is a chemotherapy medication used for the treatment of Hodgkin's lymphoma and brain cancers. For Hodgkin's it is often used together with mechlorethamine, vincristine, and prednisone while for brain cancers such as glioblastoma multiforme it is used with lomustine and vincristine. It is typically taken by mouth.
Common side effect include low blood cell counts and vomiting. Other side effects include tiredness and depression. It is not recommended in people with severe liver or kidney problems. Use in pregnancy is known to harm the baby. Procarbazine is in the alkylating agents family of medication. How it works is not clearly known.
Procarbazine was approved for medical use in the United States in 1969. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. In the United Kingdom a month of treatment cost the NHS 450 to 750 pounds.
When used to treat Hodgkin's lymphoma, it is often delivered as part of the BEACOPP regimen that includes bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine (tradename Oncovin), prednisone, and procarbazine. The first combination chemotherapy developed for Hodgkin's lymphoma (HL), MOPP also included procarbazine (ABVD has supplanted MOPP as standard first line treatment for HL, with BEACOPP as an alternative for advanced/unfavorable HL). Alternatively, when used to treat certain brain tumors (malignant gliomas), it is often dosed as PCV when combined with lomustine (often called CCNU) and vincristine.
...
Wikipedia